Table 2.

Observational and retrospective studies.

	Participants' characteristics			Baclofen Treatment		Clinical effects of baclofen treatment
References	Gender	Comorbidity	Baseline DDD	Mean daily dose	Weeks of treatment	Alcohol	Anxiety	Depression
(27, 36)	70 M 30 F	Other psychiatric disorders (59%) Anxiety disorders (53%) Depression (34%)	M = 19 F = 15	M = 158 mg F = 127 mg	104	↓	After 3 months, the rate of participants who continued to drink at risk levels was higher among participants with mental disorders (70%) than without (48%)
(37)	10 M 3 F	Anxiety (62%) Depression (100%)	~9-33	30-150 mg	Up to 108	↓	Some ↓	-
(38)	31 M 22 F	Liver disease (100%)	20	60 mg	104	↓	↔	↔
(28)	59 M 57 F	Other psychiatric disorders (92%) Anxiety disorders (75%) Depression (56%)	M = ~16 F = ~12	150 mg	52	↓	After 12 months, the rate of participants with mental disorders was higher among non-abstinent participants (48%) than abstinent participants (12%)
(29)	39 M 30 F	23 patients with BPD vs. 46 patients without BPD	At least 8	-	~32	↔ BPD ↓ Controls	After a serious adverse event, the rate of treatment discontinuation was higher among participants with BPD (65%) than without BPD (6%)
(39)	112 M 1 F	Number of patients with comorbid psychiatric illness not provided	–	–	–	↓	–	–
(40)	348 M	No other mental disorders	~12.5	50 mg		↓	–	–
(41)	20 M 15 F	Patients with or without cirrhosis Number of patients with comorbid psychiatric illness not provided	-	30 mg	>23	↓	–	–

BPD, Borderline Personality Disorder; DDD: Drinks per Drinking Day (1 drink = 12 g of pure alcohol); F: Female; M, Male. Italic indicates rates of participants suffering for the other disorder.